Literature DB >> 29129607

Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects.

Tatiane Assone1, Fernanda M Malta2, Sonia Bakkour3, Leilani Montalvo3, Arthur M Paiva1, Jerusa Smid4, Augusto César Penalva de Oliveira4, Fernanda de Toledo Gonçalves5, Olinda do Carmo Luiz6, Luiz Augusto M Fonseca6, Philip J Norris7, Jorge Casseb8.   

Abstract

INTRODUCTION: Several genetic polymorphisms may be related to susceptibility or resistance to viral disease outcomes. Immunological or genetic factors may act as major triggers of the immune pathogenesis of HAM/TSP. This study investigated the association of immune related genetic polymorphisms with viral and immunological markers.
METHODS: 247 HTLV-1-infected volunteers, drawn from a larger group of HTLV-infected subjects followed at the Institute of Infectious Diseases "Emilio Ribas" (IIER) for up to 19 years, participated in this study, which ran from June 2011 to July 2016. The subjects were classified according to their neurological status into two groups: Group 1 (160 asymptomatic individuals) and Group 2 (87 HAM/TSP patients). Samples were tested for spontaneous lymphocyte proliferation (LPA) and HTLV-1 proviral load (PVL) and for IFN-λ4, HLA-C and KIR genotypes using qPCR.
RESULTS: We found associations between LPA (p=0.0001) with HAM/TSP and confirmed the IFN-λ4 polymorphism rs8099917, allele GG, as a protective factor using a recessive model (OR=3.22, CI=1.10-9.47). Polymorphisms in HLA-C and KIR alleles were not associated with risk of developing HAM/TSP.
CONCLUSION: We demonstrated that age, LPA and an IFN-λ4 polymorphism were associated with progression to HAM/TSP. Understanding HAM/TSP pathogenesis can provide important markers of prognostic value for clinical management, and contribute to the discovery of new therapeutic interventions in the future.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HLA antigens; HTLV-1; Interferons; Polymorphisms

Mesh:

Substances:

Year:  2017        PMID: 29129607     DOI: 10.1016/j.virusres.2017.11.010

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  The SAMHD1 rs6029941 (A/G) Polymorphism Seems to Influence the HTLV-1 Proviral Load and IFN-Alpha Levels.

Authors:  Maria Alice Freitas Queiroz; Ednelza da Silva Graça Amoras; Tuane Carolina Ferreira Moura; Carlos Araújo da Costa; Maisa Silva de Sousa; Sandra Souza Lima; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Front Cell Infect Microbiol       Date:  2020-05-25       Impact factor: 5.293

2.  TREX1 531C>T Polymorphism is Associated with High Proviral Load Levels in HTLV-1-Infected Persons.

Authors:  Denis de Castro Silva; Ednelza da Silva Graça Amoras; Tuane Carolina Ferreira Moura; Felipe Teixeira Lopes; Samara Tatielle Monteiro Gomes; Carlos A da Costa; Maísa Silva Sousa; Ricardo Ishak; Antonio Carlos Rosário Vallinoto; Maria Alice Freitas Queiroz
Journal:  Viruses       Date:  2019-12-19       Impact factor: 5.048

Review 3.  Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.

Authors:  Antonio Carlos Rosário Vallinoto; Izaura Cayres-Vallinoto; Maria Alice Freitas Queiroz; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Viruses       Date:  2019-10-23       Impact factor: 5.048

4.  Dichotomy in Fatal Outcomes in a Large Cohort of People Living with HTLV-1 in São Paulo, Brazil.

Authors:  Rosa Maria N Marcusso; Johan Van Weyenbergh; João Victor Luisi de Moura; Flávia Esper Dahy; Aline de Moura Brasil Matos; Michel E J Haziot; Jose E Vidal; Luiz Augusto M Fonseca; Jerusa Smid; Tatiane Assone; Jorge Casseb; Augusto César Penalva de Oliveira
Journal:  Pathogens       Date:  2019-12-26

Review 5.  Pathogenesis of HTLV-1 infection and progression biomarkers: An overview.

Authors:  Carlos Brites; Maria Fernanda Grassi; Juarez Antônio Simões Quaresma; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Braz J Infect Dis       Date:  2021-07-10       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.